Registry update — unassessed
Improving Physical Ability and Cellular Senescence Elimination in HIV
Trial registry update: COMPLETED. No results reported in the supplied registry record.
RCTN=80Routine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 15, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- The abstract reports only the protocol, not outcomes—it is unclear whether the trial found any benefit, harm, or difference between groups.
- The study is small (80 participants) and in a specific population (older people with HIV), so any findings would not necessarily apply to other populations or ages.
- A 12-week intervention period may be too short to determine durable effects on physical function or cellular senescence.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 80
- Duration
- 24 months
- Population
- People with HIV aged 50 or older who have been living with HIV for at least 10 years, meeting criteria for frail or prefrail diagnosis, and currently on stable antiretroviral therapy with viral suppression
- Primary outcome
- Physical function
- Effect size
- —
- Significance
- Not reported
- Journal
- National Institute of Allergy and Infectious Diseases (NIAID)
- Published
- Sep 15, 2026
Sources
Primary source
Recorded source passages
Abstract or registry material supplied for assessment; source version 2. This is not a claim of full-text review.
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail.
The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression.
Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo.
The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment.
After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects.
Randomization will be stratified by sex and age to ensure balanced groups.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.